

CITATION REPORT

List of articles citing

Phosphodiesterase type 5 inhibitors: state of the therapeutic class

DOI: 10.1016/j.ucl.2007.08.013

Urologic Clinics of North America, 2007, 34, 507-15, vi.

Source: <https://exaly.com/paper-pdf/42125978/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
24	Tadalafil in the treatment of erectile dysfunction. <i>Therapeutics and Clinical Risk Management</i> , 2008 , 4, 1315-30	2.9	57
23	Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2009 , 1, 235-42	3.2	7
22	2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. <i>Journal of Sexual Medicine</i> , 2009 , 6, 2352-64; quiz 2365-6	1.1	31
21	Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications. <i>Pharmacogenomics</i> , 2009 , 10, 1625-44	2.6	9
20	Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. <i>Journal of Sexual Medicine</i> , 2010 , 7, 89-98	1.1	103
19	Newer phosphodiesterase inhibitors: comparison with established agents. <i>Urologic Clinics of North America</i> , 2011 , 38, 155-63	2.9	10
18	Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2883-93	1.1	20
17	Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. <i>Clinical Therapeutics</i> , 2011 , 33, 1590-608	3.5	10
16	Sildenafil does not improve steady state cardiovascular hemodynamics, peak power, or 15-km time trial cycling performance at simulated moderate or high altitudes in men and women. <i>European Journal of Applied Physiology</i> , 2011 , 111, 3031-40	3.4	18
15	Tadalafil inclusion in microporous silica as effective dissolution enhancer: optimization of loading procedure and molecular state characterization. <i>Journal of Pharmaceutical Sciences</i> , 2011 , 100, 1805-18	3.9	33
14	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. <i>Physiological Reviews</i> , 2011 , 91, 651-90	47.9	443
13	Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis. <i>Urologia Internationalis</i> , 2013 , 91, 10-8	1.9	28
12	Contemporary management of erectile dysfunction. <i>Urological Science</i> , 2013 , 24, 35-40	0.3	2
11	Erectile dysfunction. <i>Lancet, The</i> , 2013 , 381, 153-65	4.0	545
10	Tadalafil oral disintegrating tablets: an approach to enhance tadalafil dissolution. <i>Journal of Pharmaceutical Investigation</i> , 2015 , 45, 481-491	6.3	12
9	Nanovesicular carrier-mediated transdermal delivery of tadalafil: i-formulation and physicochemical characterization. <i>Drug Development and Industrial Pharmacy</i> , 2015 , 41, 714-21	3.6	15
8	Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors. <i>Scientia Pharmaceutica</i> , 2015 , 84, 428-446	4.3	4

7	Treating male sexual dysfunction after traumatic brain injury: Two case reports. <i>NeuroRehabilitation</i> , 2016 , 38, 281-9	2	7
6	Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. <i>Journal of Endocrinological Investigation</i> , 2016 , 39, 143-51	5.2	22
5	Molecular Docking Analysis of Anti-Severe Acute Respiratory Syndrome-Coronavirus 2 Ligands against Spike Glycoprotein and the 3-Chymotrypsin-Like Protease. <i>Journal of Medical Signals and Sensors</i> , 2021 , 11, 31-36	1	1
4	A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2013 , 49, 1-11	1.8	16
3	Erectile Dysfunction. 2013 , 129-134		
2	Urologic/Clinical Treatment of Erectile Dysfunction. 2016 , 53-63		
1	Erectile Dysfunction: Medical Therapy and Rehabilitation. 2023 , 35-45		0